More about our device:

Taking cues from cutting edge technology in coronary artery stenting (such as Abbott's ABSORB® Bioresorbable Vascular Scaffold) and non-surgical aneurysm treatment (such as Covidien's Pipeline® Embolization Device), Pegasus Therapeutics is designing a Bioresorbable Flow Diverter to give young patients with coronary artery aneurysms a more suitable treatment option that avoids open heart surgery, allowing the body's natural healing response to take place.  By designing a device that resorbs (dissolves) back into the body, our goal is to leave the artery healed without restricting future vessel growth or limiting options for other treatment that may be needed later in life. 

Who will this help?

This device was inspired by the 20,000 kids like Allison in the US, and many more world-wide, who are living with coronary aneurysms that may eventually need treatment. In addition, our technology will help pave the way to improved therapies for the 8 million people in the United States with arterial aneurysms in the cerebral, coronary, and peripheral vasculature who could benefit from a similar procedure.  

How it works:

After being delivered to the coronary artery through a catheter (similar to how a stent is deployed), our Bioresorbable Flow Diverter limits blood flow to the aneurysm while keeping the main artery open.  This gives the body a chance to heal the aneurysm naturally - first through a gradual clotting process, and then by creating a new vessel lining that seals it off. As the flow diverter gradually resorbs, the aneurysm has further opportunity to heal, allowing the body to take over its natural function of pumping blood through the remodeled artery.

For more in-depth information, please see our Technical Information Series:

(Click on topic for video link)